← Back to Zydus Lifesciences Ltd. overview
Zydus Lifesciences Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹22,574 cr | ₹4,526 cr | ₹44.97 | ₹37,202 cr | ₹23,953 cr | 18.89% | 22.53% | 0.13x | 20.05% |
| FY2024 | ₹19,022 cr | ₹3,860 cr | ₹38.14 | ₹29,281 cr | ₹19,830 cr | 19.46% | 23.52% | 0.04x | 20.29% |
| FY2023 | ₹16,878 cr | ₹1,960 cr | ₹19.3 | ₹25,756 cr | ₹17,516 cr | 11.19% | 14.51% | 0.07x | 11.61% |
| FY2022 | ₹14,828 cr | ₹4,487 cr | ₹43.83 | ₹27,795 cr | ₹17,000 cr | 26.4% | 13.91% | 0.25x | 30.26% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.